Stabilized Outersurface Protein A Fragment as a Lyme Disease Vaccine

Applications

Lyme disease is a tick-borne infection caused by the spirochete Borrelia burgdorferi that can result in damages to joints, cardiovascular and nervous systems. Outsurface protein A (OspA) is a major surface antigen of Borrelia burgdorferi. Anti- OspA mAb has been shown to protect severe combined immunodeficiency mice from clinical symptoms of Lyme disease, suggesting that the Anti- OspA mAb blocks spirochete transmission by binding to OspA. The invention develops site-directed mutations of OspA whose fold conformation is stable.

 

Advantages

The invention develops a stabilized small segment of OspA as a vaccine for Lyme disease. The invention reduces potential side effects of a full length OspA.

URV Reference Number: 6-1128
Patent Information:
Category(s):
Vaccines
For Information, Contact:
Blaze Pharoah
Licensing Manager
University of Rochester
585-276-6600
blaze_pharoah@urmc.rochester.edu
Inventors:
Shohei Koide
Benjamin Luft
John Dunn
Catherine Lawson
Keywords:
Vaccine